VANCOUVER, Nov. 12 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX: COM) today announced that it will report 2007 third quarterfinancial results on the afternoon of Tuesday, November 13, 2007. Cardiomewill hold a teleconference call and webcast at 4:30pm Eastern Time (1:30pmPacific Time) on that day to discuss the results.
To access the conference call, please dial 416-340-8010 or 866-540-8136.There will be a separate dial-in line for analysts on which we will respond toquestions at the end of the call. The webcast can be accessed throughCardiome's website at www.cardiome.com.
Webcast and telephone replays of the conference call will be availableapproximately two hours after the completion of the call through December 10,2007. Please dial 416-695-5800 or 800-408-3053 and enter code 3242180 followedby the number sign to access the replay.
Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995 or forward-looking information under applicable Canadian securitieslegislation that may not be based on historical fact, including withoutlimitation statements containing the words "believe", "may", "plan", "will","estimate", "continue", "anticipate", "intend", "expect" and similarexpressions. Such forward-looking statements or information involve known andunknown risks, uncertainties and other factors that may cause our actualresults, events or developments, or industry results, to be materiallydifferent from any future results, events or developments expressed or impliedby such forward-looking statements or information. Such factors include, amongothers, our stage of development, lack of product revenues, additional capitalrequirements, risk associated with the completion of clinical trials andobtaining regulatory approval to market our products, the ability to protectour intellectual property, dependence on collaborative partners and theprospects for negotiating additional corporate collaborations or licensingarrangements and their timing. Specifically, certain risks and uncertaintiesthat could cause such actual events or results expressed or implied by suchforward-looking statements and information to differ materially from anyfuture events or results expressed or implied by such statements andinformation include, but are not limited to, the risks and uncertainties that:we may not be able to successfully develop and obtain regulatory approval forvernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillationor any other current or future products in our targeted indications; ourfuture operating results are uncertain and likely to fluctuate; we may not beable to raise additional capital; we may not be successful in establishingadditional corporate collaborations or licensing arrangements; we may not beable to establish marketing and sales capabilities and the costs of launchingour products may be greater than anticipated; we rely on third parties for thecontinued supply and manufacture of vernakalant (iv) and vernakalant (oral)and we have no experience in commercial manufacturing; we may face unknownrisks related to intellectual property matters; we face increased competitionfrom pharmaceutical and biotechnology companies; and other factors asdescribed in detail in our filings with the Securities and Exchange Commissionavailable at www.sec.gov and the Canadian securities regulatory authorities atwww.sedar.com. Given these risks and uncertainties, you are cautioned not toplace undue reliance on such forward-looking statements and information, whichare qualified in their entirety by this cautionary statement. Allforward-looking statements and information made herein are based on ourcurrent expectations and we undertake no obligation to revise or update suchforward-looking statements and in